Canada: These 63 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Canada
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: Canada: These 63 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
| Tradename | Ingredient | Estimated Entry Opportunity Date |
|---|---|---|
| QVAR REDIHALER | beclomethasone dipropionate | 2027-04-11 |
| CREON | pancrelipase (amylase;lipase;protease) | 2026-08-15 |
| PANCREAZE | pancrelipase (amylase;lipase;protease) | 2027-02-20 |
| ZENPEP | pancrelipase (amylase;lipase;protease) | 2027-02-20 |
| RYTARY | carbidopa; levodopa | 2027-12-28 |
| CRESEMBA | isavuconazonium sulfate | 2026-09-25 |
| >Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: Canada: These 63 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch?
Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 11, 2027
Generic Entry Controlled by: Canada Patent 2,682,528
This drug has two hundred and seventy-eight patent family members in twenty-seven countries. There has been litigation on patents covering QVAR REDIHALER
See drug price trends for QVAR REDIHALER.
The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2026
Generic Entry Controlled by: Canada Patent 2,619,475
CREON is a drug marketed by
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2026
Generic Entry Controlled by: Canada Patent 2,619,477
CREON is a drug marketed by
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 20, 2027
Generic Entry Controlled by: Canada Patent 2,677,989
PANCREAZE is a drug marketed by
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 20, 2027
Generic Entry Controlled by: Canada Patent 2,677,989
ZENPEP is a drug marketed by
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can RYTARY (carbidopa; levodopa) generic drug versions launch?
Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 28, 2027
Generic Entry Controlled by: Canada Patent 2,711,014
RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges.
This drug has twenty-five patent family members in twelve countries. There has been litigation on patents covering RYTARY
See drug price trends for RYTARY.
The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this API. Thirty-eight suppliers are listed for this generic product. Additional details are available on the carbidopa; levodopa profile page.
When can CRESEMBA (isavuconazonium sulfate) generic drug versions launch?
Generic name: isavuconazonium sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 25, 2026
Generic Entry Controlled by: Canada Patent 2,663,941
This drug has thirty-two patent family members in nineteen countries. There has been litigation on patents covering CRESEMBA
See drug price trends for CRESEMBA.
The generic ingredient in CRESEMBA is isavuconazonium sulfate. One supplier is listed for this generic product. Additional details are available on the isavuconazonium sulfate profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: Canada Patent 2,620,380
ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Canada Patent 2,653,344
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 18, 2026
Generic Entry Controlled by: Canada Patent 2,634,073
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can VIZAMYL (flutemetamol f-18) generic drug versions launch?
Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 30, 2027
Generic Entry Controlled by: Canada Patent 2,694,084
VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.
This drug has twenty-three patent family members in twenty countries.
See drug price trends for VIZAMYL.
The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this generic product. Additional details are available on the flutemetamol f-18 profile page.
When can INTRAROSA (prasterone) generic drug versions launch?
Generic name: prasterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 10, 2027
Generic Entry Controlled by: Canada Patent 2,696,127
This drug has fifty-nine patent family members in thirty-two countries. There has been litigation on patents covering INTRAROSA
See drug price trends for INTRAROSA.
The generic ingredient in INTRAROSA is prasterone. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the prasterone profile page.
When can INTRAROSA (prasterone) generic drug versions launch?
Generic name: prasterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 10, 2027
Generic Entry Controlled by: Canada Patent 2,820,566
This drug has fifty-nine patent family members in thirty-two countries. There has been litigation on patents covering INTRAROSA
See drug price trends for INTRAROSA.
The generic ingredient in INTRAROSA is prasterone. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the prasterone profile page.
When can SALONPAS (menthol; methyl salicylate) generic drug versions launch?
Generic name: menthol; methyl salicylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 04, 2026
Generic Entry Controlled by: Canada Patent 2,652,220
SALONPAS is a drug marketed by Hisamitsu Pharm Co. There are two patents protecting this drug.
This drug has twenty patent family members in sixteen countries.
The generic ingredient in SALONPAS is menthol; methyl salicylate. There are eighteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the menthol; methyl salicylate profile page.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?
Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 24, 2027
Generic Entry Controlled by: Canada Patent 2,683,935
SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.
See drug price trends for SIGNIFOR LAR.
The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 26, 2027
Generic Entry Controlled by: Canada Patent 2,644,530
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.
When can AXUMIN (fluciclovine f-18) generic drug versions launch?
Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 28, 2026
Generic Entry Controlled by: Canada Patent 2,629,227
AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.
This drug has thirty patent family members in sixteen countries. There has been litigation on patents covering AXUMIN
The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: Canada Patent 2,690,841
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: Canada Patent 2,789,109
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.
When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch?
Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 16, 2027
Generic Entry Controlled by: Canada Patent 2,700,444
This drug has one hundred and thirty-six patent family members in thirty-six countries. There has been litigation on patents covering VELPHORO
See drug price trends for VELPHORO.
The generic ingredient in VELPHORO is sucroferric oxyhydroxide. There are four drug master file entries for this API. Additional details are available on the sucroferric oxyhydroxide profile page.
When can VANTRELA ER (hydrocodone bitartrate) generic drug versions launch?
Generic name: hydrocodone bitartrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 15, 2026
Generic Entry Controlled by: Canada Patent 2,663,172
VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.
When can BRILINTA (ticagrelor) generic drug versions launch?
Generic name: ticagrelor
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 21, 2026
Generic Entry Controlled by: Canada Patent 2,659,328
This drug has sixty-two patent family members in thirty-five countries. There has been litigation on patents covering BRILINTA
See drug price trends for BRILINTA.
The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-eight suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.
When can EDARBI (azilsartan kamedoxomil) generic drug versions launch?
Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 28, 2027
Generic Entry Controlled by: Canada Patent 2,681,143
This drug has twenty-one patent family members in seventeen countries. There has been litigation on patents covering EDARBI
See drug price trends for EDARBI.
The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the azilsartan kamedoxomil profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Canada Patent 2,653,344
This drug has four hundred and twenty-seven patent family members in fifty-three countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can INLYTA (axitinib) generic drug versions launch?
Generic name: axitinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 05, 2027
Generic Entry Controlled by: Canada Patent 2,682,859
INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has one hundred and two patent family members in thirty-one countries. There has been litigation on patents covering INLYTA
See drug price trends for INLYTA.
The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the axitinib profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Canada Patent 2,689,663
JAKAFI is a drug marketed by Incyte Corp. There are twenty-five patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can LETAIRIS (ambrisentan) generic drug versions launch?
Generic name: ambrisentan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Canada Patent 2,669,536
LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-one patent family members in twenty-six countries. There has been litigation on patents covering LETAIRIS
See drug price trends for LETAIRIS.
The generic ingredient in LETAIRIS is ambrisentan. There are nine drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the ambrisentan profile page.
When can NESINA (alogliptin benzoate) generic drug versions launch?
Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: Canada Patent 2,677,193
This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA
See drug price trends for NESINA.
The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.
When can OPSUMIT (macitentan) generic drug versions launch?
Generic name: macitentan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 29, 2026
Generic Entry Controlled by: Canada Patent 2,659,770
OPSUMIT is a drug marketed by Actelion. There are five patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and one patent family members in thirty-five countries. There has been litigation on patents covering OPSUMIT
See drug price trends for OPSUMIT.
The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this API. Fourteen suppliers are listed for this generic product. Additional details are available on the macitentan profile page.
When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch?
Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: Canada Patent 2,677,201
This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI
See drug price trends for OSENI.
The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 03, 2027
Generic Entry Controlled by: Canada Patent 2,685,831
PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Canada Patent 2,653,344
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2027
Generic Entry Controlled by: Canada Patent 2,668,512
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
This drug has ninety-seven patent family members in thirty-nine countries.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 30, 2027
Generic Entry Controlled by: Canada Patent 2,649,922
This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can ZEMDRI (plazomicin sulfate) generic drug versions launch?
Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 21, 2027
Generic Entry Controlled by: Canada Patent 2,706,369
ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug.
This drug has twenty-eight patent family members in twenty-one countries. There has been litigation on patents covering ZEMDRI
See drug price trends for ZEMDRI.
The generic ingredient in ZEMDRI is plazomicin sulfate. Three suppliers are listed for this generic product. Additional details are available on the plazomicin sulfate profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 20, 2027
Generic Entry Controlled by: Canada Patent 2,678,795
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.
This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. One supplier is listed for this generic product. Additional details are available on the lefamulin acetate profile page.
When can BYFAVO (remimazolam besylate) generic drug versions launch?
Generic name: remimazolam besylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: Canada Patent 2,657,347
BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.
This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO
See drug price trends for BYFAVO.
The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.
When can TRELSTAR (triptorelin pamoate) generic drug versions launch?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 06, 2027
Generic Entry Controlled by: Canada Patent 2,688,478
TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
See drug price trends for TRELSTAR.
The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can WINLEVI (clascoterone) generic drug versions launch?
Generic name: clascoterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: Canada Patent 2,691,445
This drug has ninety-four patent family members in thirty countries. There has been litigation on patents covering WINLEVI
See drug price trends for WINLEVI.
The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.
When can WINLEVI (clascoterone) generic drug versions launch?
Generic name: clascoterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: Canada Patent 2,871,025
This drug has ninety-four patent family members in thirty countries. There has been litigation on patents covering WINLEVI
See drug price trends for WINLEVI.
The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.
When can WINLEVI (clascoterone) generic drug versions launch?
Generic name: clascoterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: Canada Patent 2,871,039
This drug has ninety-four patent family members in thirty countries. There has been litigation on patents covering WINLEVI
See drug price trends for WINLEVI.
The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.
When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch?
Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Canada Patent 2,693,600
TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.
This drug has eighty patent family members in thirty-seven countries. There has been litigation on patents covering TEPMETKO
See drug price trends for TEPMETKO.
The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 13, 2027
Generic Entry Controlled by: Canada Patent 2,667,460
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 10, 2026
Generic Entry Controlled by: Canada Patent 2,898,514
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch?
Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 12, 2027
Generic Entry Controlled by: Canada Patent 2,702,152
PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering PREPOPIK
See drug price trends for PREPOPIK.
The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.
When can SOLUPREP (chlorhexidine gluconate; isopropyl alcohol) generic drug versions launch?
Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 31, 2027
Generic Entry Controlled by: Canada Patent 2,711,217
SOLUPREP is a drug marketed by Solventum.
The generic ingredient in SOLUPREP is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Canada Patent 2,672,233
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
This drug has seventy patent family members in twenty-nine countries.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.
When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch?
Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 08, 2026
Generic Entry Controlled by: Canada Patent 2,590,511
This drug has one hundred and eight patent family members in thirty-nine countries. There has been litigation on patents covering ENTRESTO SPRINKLE
See drug price trends for ENTRESTO SPRINKLE.
The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Twenty-seven suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.
When can ZUNVEYL (benzgalantamine gluconate) generic drug versions launch?
Generic name: benzgalantamine gluconate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: Canada Patent 2,623,114
ZUNVEYL is a drug marketed by Alpha Cognition. There are four patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering ZUNVEYL
The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.
When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 06, 2027
Generic Entry Controlled by: Canada Patent 2,688,478
TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can REVLIMID (lenalidomide) generic drug versions launch?
Generic name: lenalidomide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 03, 2026
Generic Entry Controlled by: Canada Patent 2,570,755
REVLIMID is a drug marketed by Bristol Myers Squibb. There are two patents protecting this drug and three Paragraph IV challenges.
This drug has three hundred and thirty-one patent family members in forty-one countries. There has been litigation on patents covering REVLIMID
See drug price trends for REVLIMID.
The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the lenalidomide profile page.
When can REVLIMID (lenalidomide) generic drug versions launch?
Generic name: lenalidomide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 03, 2026
Generic Entry Controlled by: Canada Patent 2,972,299
REVLIMID is a drug marketed by Bristol Myers Squibb. There are two patents protecting this drug and three Paragraph IV challenges.
This drug has three hundred and thirty-one patent family members in forty-one countries. There has been litigation on patents covering REVLIMID
See drug price trends for REVLIMID.
The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the lenalidomide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 29, 2027
Generic Entry Controlled by: Canada Patent 2,648,139
XTANDI is a drug marketed by Astellas. There are seven patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.
This drug has one hundred and ninety-two patent family members in thirty-six countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can EUCRISA (crisaborole) generic drug versions launch?
Generic name: crisaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2026
Generic Entry Controlled by: Canada Patent 2,635,680
This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA
See drug price trends for EUCRISA.
The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.
When can KERYDIN (tavaborole) generic drug versions launch?
Generic name: tavaborole
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2026
Generic Entry Controlled by: Canada Patent 2,635,680
See drug price trends for KERYDIN.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 26, 2027
Generic Entry Controlled by: Canada Patent 2,655,596
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries. There has been litigation on patents covering APLENZIN
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can AURYXIA (ferric citrate) generic drug versions launch?
Generic name: ferric citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 18, 2026
Generic Entry Controlled by: Canada Patent 2,619,591
This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA
See drug price trends for AURYXIA.
The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.
When can AURYXIA (ferric citrate) generic drug versions launch?
Generic name: ferric citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: January 26, 2027
Generic Entry Controlled by: Canada Patent 2,640,763
This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA
See drug price trends for AURYXIA.
The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.
When can AURYXIA (ferric citrate) generic drug versions launch?
Generic name: ferric citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: January 26, 2027
Generic Entry Controlled by: Canada Patent 2,640,974
This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA
See drug price trends for AURYXIA.
The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.
When can AURYXIA (ferric citrate) generic drug versions launch?
Generic name: ferric citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 18, 2026
Generic Entry Controlled by: Canada Patent 3,050,453
This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA
See drug price trends for AURYXIA.
The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 26, 2026
Generic Entry Controlled by: Canada Patent 2,626,956
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-six patent family members in thirty-three countries. There has been litigation on patents covering VOCABRIA
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can TYMLOS (abaloparatide) generic drug versions launch?
Generic name: abaloparatide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 03, 2026
Generic Entry Controlled by: Canada Patent 2,664,734
This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS
See drug price trends for TYMLOS.
The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.
When can LIVDELZI (seladelpar lysine) generic drug versions launch?
Generic name: seladelpar lysine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 13, 2026
Generic Entry Controlled by: Canada Patent 2,622,722
LIVDELZI is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.
This drug has one hundred and thirty-eight patent family members in forty-six countries.
The generic ingredient in LIVDELZI is seladelpar lysine. One supplier is listed for this generic product. Additional details are available on the seladelpar lysine profile page.
When can SOFDRA (sofpironium bromide) generic drug versions launch?
Generic name: sofpironium bromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 13, 2026
Generic Entry Controlled by: Canada Patent 2,627,982
SOFDRA is a drug marketed by Botanix Sb. There are twenty patents protecting this drug.
This drug has one hundred and sixty-six patent family members in twenty-six countries. There has been litigation on patents covering SOFDRA
The generic ingredient in SOFDRA is sofpironium bromide. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the sofpironium bromide profile page.
When can CARDAMYST (etripamil) generic drug versions launch?
Generic name: etripamil
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 20, 2027
Generic Entry Controlled by: Canada Patent 2,693,627
This drug has sixty-six patent family members in twenty-nine countries. There has been litigation on patents covering CARDAMYST
See drug price trends for CARDAMYST.
The generic ingredient in CARDAMYST is etripamil. One supplier is listed for this generic product. Additional details are available on the etripamil profile page.
When can ORENITRAM (treprostinil diolamine) generic drug versions launch?
Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 17, 2027
Generic Entry Controlled by: Canada Patent 2,710,205
ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges.
This drug has fifty-nine patent family members in eight countries. There has been litigation on patents covering ORENITRAM
See drug price trends for ORENITRAM.
The generic ingredient in ORENITRAM is treprostinil diolamine. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the treprostinil diolamine profile page.
When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch?
Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 09, 2027
Generic Entry Controlled by: Canada Patent 2,660,520
This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA
See drug price trends for DAKLINZA.
The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 07, 2027
Generic Entry Controlled by: Canada Patent 2,706,920
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug.
This drug has four hundred and sixty-one patent family members in thirty-six countries. There has been litigation on patents covering ORKAMBI
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 07, 2027
Generic Entry Controlled by: Canada Patent 2,986,286
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug.
This drug has four hundred and sixty-one patent family members in thirty-six countries. There has been litigation on patents covering ORKAMBI
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can VARUBI (rolapitant hydrochloride) generic drug versions launch?
Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 04, 2027
Generic Entry Controlled by: Canada Patent 2,648,604
VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.
This drug has one hundred and fifty-eight patent family members in thirty-five countries.
The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.
When can DUZALLO (allopurinol; lesinurad) generic drug versions launch?
Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 27, 2027
Generic Entry Controlled by: Canada Patent 2,735,828
This drug has one hundred and forty-four patent family members in thirty-nine countries. There has been litigation on patents covering DUZALLO
See drug price trends for DUZALLO.
The generic ingredient in DUZALLO is allopurinol; lesinurad. There are twenty-two drug master file entries for this API. Additional details are available on the allopurinol; lesinurad profile page.
When can ZURAMPIC (lesinurad) generic drug versions launch?
Generic name: lesinurad
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 27, 2027
Generic Entry Controlled by: Canada Patent 2,735,828
ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug.
This drug has one hundred and forty-four patent family members in thirty-nine countries. There has been litigation on patents covering ZURAMPIC
See drug price trends for ZURAMPIC.
The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.
When can ZYKADIA (ceritinib) generic drug versions launch?
Generic name: ceritinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 08, 2026
Generic Entry Controlled by: Canada Patent 2,671,744
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch?
Generic name: ceritinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 08, 2026
Generic Entry Controlled by: Canada Patent 2,696,824
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can BEVYXXA (betrixaban) generic drug versions launch?
Generic name: betrixaban
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 07, 2026
Generic Entry Controlled by: Canada Patent 2,627,086
BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.
This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA
See drug price trends for BEVYXXA.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
When can MULPLETA (lusutrombopag) generic drug versions launch?
Generic name: lusutrombopag
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 31, 2027
Generic Entry Controlled by: Canada Patent 2,694,567
MULPLETA is a drug marketed by Vancocin Italia. There are three patents protecting this drug.
This drug has forty-one patent family members in twenty countries.
See drug price trends for MULPLETA.
The generic ingredient in MULPLETA is lusutrombopag. Three suppliers are listed for this generic product. Additional details are available on the lusutrombopag profile page.
When can ONPATTRO (patisiran sodium) generic drug versions launch?
Generic name: patisiran sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 27, 2027
Generic Entry Controlled by: Canada Patent 2,721,333
ONPATTRO is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug.
This drug has two hundred and fifty-two patent family members in thirty-one countries. There has been litigation on patents covering ONPATTRO
See drug price trends for ONPATTRO.
The generic ingredient in ONPATTRO is patisiran sodium. One supplier is listed for this generic product. Additional details are available on the patisiran sodium profile page.
When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch?
Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 09, 2027
Generic Entry Controlled by: Canada Patent 2,648,719
SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug.
This drug has four hundred and twenty-eight patent family members in forty-one countries. There has been litigation on patents covering SYMDEKO (COPACKAGED)
The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.
When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch?
Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 09, 2027
Generic Entry Controlled by: Canada Patent 2,869,945
SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug.
This drug has four hundred and twenty-eight patent family members in forty-one countries. There has been litigation on patents covering SYMDEKO (COPACKAGED)
The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.
When can SEYSARA (sarecycline hydrochloride) generic drug versions launch?
Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 21, 2026
Generic Entry Controlled by: Canada Patent 2,673,486
SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.
This drug has seventy-three patent family members in twenty countries.
See drug price trends for SEYSARA.
The generic ingredient in SEYSARA is sarecycline hydrochloride. One supplier is listed for this generic product. Additional details are available on the sarecycline hydrochloride profile page.
When can SEYSARA (sarecycline hydrochloride) generic drug versions launch?
Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 21, 2027
Generic Entry Controlled by: Canada Patent 2,892,739
SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.
This drug has seventy-three patent family members in twenty countries.
See drug price trends for SEYSARA.
The generic ingredient in SEYSARA is sarecycline hydrochloride. One supplier is listed for this generic product. Additional details are available on the sarecycline hydrochloride profile page.
When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch?
Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2027
Generic Entry Controlled by: Canada Patent 2,671,614
ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.
This drug has one hundred and five patent family members in forty-eight countries.
See drug price trends for ALIQOPA.
The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.
When can KLISYRI (tirbanibulin) generic drug versions launch?
Generic name: tirbanibulin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 29, 2027
Generic Entry Controlled by: Canada Patent 2,656,564
KLISYRI is a drug marketed by Almirall. There are six patents protecting this drug.
This drug has one hundred and forty-two patent family members in thirty-two countries. There has been litigation on patents covering KLISYRI
See drug price trends for KLISYRI.
The generic ingredient in KLISYRI is tirbanibulin. One supplier is listed for this generic product. Additional details are available on the tirbanibulin profile page.